



PCO₂ AND CALCULATED VALUES FOR HCO₃⁻, BASE EXCESS AND ANION GAP

PCO₂ is measured by direct potentiometry. In the calculation of results for PCO₂, concentration is related to potential through the Nernst equation. Results are reported at 37 °C.

Calculated Values

When a cartridge includes sensors for both pH and PCO₂, bicarbonate (HCO₃⁻), total carbon dioxide (TCO₂) and base excess (BE) are calculated.¹

$$\log \text{HCO}_3 = \text{pH} + \log \text{PCO}_2 - 7.608$$

$$\text{BE}_{\text{ecf}} = \text{HCO}_3 - 24.8 + 16.2 (\text{pH} - 7.4)$$

$$\text{BE}_b = (1 - 0.014 \cdot \text{Hb}) * [\text{HCO}_3 - 24.8 + (1.43 * \text{Hb} + 7.7) * (\text{pH} - 7.4)]$$

Anion Gap is calculated in the EC8+ and CHEM8+ cartridges as follows:

$$\text{Anion Gap (EC8+)} = (\text{Na} + \text{K}) - (\text{Cl} + \text{HCO}_3)$$

$$\text{Anion Gap (CHEM8+)} = (\text{Na} + \text{K}) - (\text{Cl} + (\text{TCO}_2 - 1))$$

See below for information on factors affecting results. Certain substances, such as drugs, may affect analyte levels *in vivo*.² If results appear inconsistent with the clinical assessment, the patient sample should be retested using another cartridge.

Intended Use

The test for PCO₂, as part of the i-STAT® System, is intended for use in the *in vitro* quantification of carbon dioxide partial pressure in arterial, venous, or capillary whole blood.

PCO₂ measurements are used in the diagnosis, monitoring, and treatment of respiratory disturbances and metabolic and respiratory-based acid-base disturbances.

Bicarbonate is used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance.

Contents

Each i-STAT cartridge contains one reference electrode (when potentiometric sensors are included in the cartridge configuration), sensors for the measurement of specific analytes, and a buffered aqueous calibrant solution that contains known concentrations of analytes and preservatives. For cartridges that contain a sensor for the measurement of PCO₂, a list of reactive ingredients is indicated below:

Reactive Ingredient	Minimum Quantity
Carbon Dioxide (CO ₂)	25.2 mmHg

Metrological Traceability

The i-STAT System test for carbon dioxide partial pressure measures carbon dioxide partial pressure in arterial, venous, or capillary whole blood (dimension kPa) for *in vitro* diagnostic use. PCO_2 values assigned to i-STAT's controls and calibration verification materials are traceable to U.S. National Institute of Standards and Technology (NIST) standard reference materials via commercially available certified specialty medical gas standards. i-STAT System controls and calibration verification materials are validated for use only with the i-STAT System and assigned values may not be commutable with other methods. Further information regarding metrological traceability is available from Abbott Point of Care Inc.

Expected Values

Test/Abbreviation	Units*	Reportable Range	Reference Range	
			(arterial)	(venous)
Partial Pressure				
Carbon Dioxide/ PCO_2	mmHg	5 – 130	35 – 45 ³	41 – 51
	kPa	0.67 – 17.33	4.67 – 6.00	5.47 – 6.80
Bicarbonate/ HCO_3	mmol/L	1.0 – 85.0	22 – 26**	23 – 28**
Base Excess/BE	mmol/L	(-30) – (+30)	(-2) – (+3) ³	(-2) – (+3) ³
Anion Gap/AnGap	mmol/L	(-10) – (+99)	10 – 20 ³	10 – 20 ³

*The i-STAT System can be configured with the preferred units.

**Calculated from Siggaard-Andersen nomogram.*

To convert PCO_2 results from mmHg to kPa, multiply the mmHg value by 0.133.

The reference ranges programmed into the analyzer and shown above are intended to be used as guides for the interpretation of results. Since reference ranges may vary with demographic factors such as age, gender and heritage, it is recommended that reference ranges be determined for the population being tested.

Clinical Significance

PCO_2 along with pH is used to assess acid-base balance. PCO_2 (partial pressure of carbon dioxide), the respiratory component of acid-base balance, is a measure of the tension or pressure of carbon dioxide dissolved in the blood. PCO_2 represents the balance between cellular production of CO_2 and ventilatory removal of CO_2 and a change in PCO_2 indicates an alteration in this balance. Causes of primary respiratory acidosis (increase in PCO_2) are airway obstruction, sedatives and anesthetics, respiratory distress syndrome, and chronic obstructive pulmonary disease. Causes of primary respiratory alkalosis (decreased PCO_2) are hypoxia (resulting in hyperventilation) due to chronic heart failure, edema and neurologic disorders, and mechanical hyperventilation.

HCO_3 (bicarbonate), the most abundant buffer in the blood plasma, is an indicator of the buffering capacity of blood. Regulated primarily by the kidneys, HCO_3 is the metabolic component of acid-base balance. Causes of primary metabolic acidosis (decrease in HCO_3) are ketoacidosis, lactate acidosis (hypoxia), and diarrhea. Causes of primary metabolic alkalosis (increase in HCO_3) are vomiting and antacid treatment.

Base excess of the extracellular fluid or standard base excess is defined as the concentration of titratable base minus the concentration of titratable acid when titrating the average intracellular fluid (plasma plus interstitial fluid) to an arterial plasma pH of 7.40 at PCO_2 of 40 mmHg at 37 °C. Excess concentration of base in the average ECF remains virtually constant during acute changes in the PCO_2 and reflects only nonrespiratory component of pH-disturbances.

Anion gap is reported as the difference between the commonly measured cations sodium and potassium and the commonly measured anions chloride and bicarbonate. The size of the gap reflects unmeasured cations and anions and is therefore an analytical gap. Physiologically, a deficit of anions cannot exist. While relatively nonspecific, anion gap is useful for the detection of organic acidosis due to an increase in anions

that are difficult to measure. Anion gap can be used to classify metabolic acidosis into high and normal anion gap types. Anion gap may be only slightly increased in diarrhea and renal failure, but elevated (often >25) due to an increase in organic anions in lactic acidosis, ketoacidosis (alcoholic, diabetic, starvation) and uremia, an increase in inorganic anions in uremia, and an increase in anions from drugs such as salicylate and carbenicillin or toxins such as methanol and ethanol.

Temperature “Correction” Algorithm

PCO_2 is a temperature-dependent quantity and is measured at 37 °C. The PCO_2 reading at a body temperature other than 37 °C can be ‘corrected’ by entering the patient’s temperature on the chart page of the analyzer. In this case, blood gas results will be displayed at both 37 °C and the patient’s temperature. The PCO_2 at the patient’s temperature (T_p) is calculated as follows:¹

$$PCO_2(T_p) = PCO_2 \times 10^{0.019(T_p-37)}$$

Note: Patient temperature corrected results are available only on cartridges containing pH, PCO_2 , and PO_2 sensors.

Performance Characteristics

The performance characteristics of the sensors are equivalent in all cartridge configurations.

The typical performance data summarized below were collected in a health care facility by health care professionals trained in the use of the i-STAT System and comparative methods.

Precision data were collected in multiple sites as follows: Duplicates of each control fluid were tested in the morning and in the afternoon on five days for a total of 20 replicates. The averaged statistics are presented below.

Method comparison data were collected using CLSI guideline EP9-A.⁵ Venous blood samples were collected in blood gas syringes. All samples were analyzed in duplicate on the i-STAT System and on the comparative methods within 10 minutes of each other. Arterial blood samples were collected from hospital patients in 3 cc blood gas syringes and were analyzed in duplicate on the i-STAT System and the comparative method within 5 minutes of each other.

Deming regression analysis⁶ was performed on the first replicate of each sample. In the method comparison table, n is the number of specimens in the data set, Sxx and Syy refer to estimates of imprecision based on the duplicates of the comparative and the i-STAT methods respectively, Sy.x is the standard error of the estimate, and r is the correlation coefficient.*

Method comparisons will vary from site to site due to differences in sample handling, comparative method calibration and other site specific variables.

* The usual warning relating to the use of regression analysis is summarized here as a reminder: For any analyte, “if the data is collected over a narrow range, the estimate of the regression parameters are relatively imprecise and may be biased. Therefore, predictions made from these estimates may be invalid”.⁷ The correlation coefficient, r, can be used as a guide to assess the adequacy of the comparative method range in overcoming this problem. As a guide, the range of data can be considered adequate if $r > 0.975$.

Precision Data (mmHg)

Aqueous Control	Mean	SD	%CV
Level 1	63.8	1.57	2.5
Level 3	19.6	0.40	2.0

Method Comparison (mmHg)

	PCO₂ IL BGE	PCO₂ Radiometer ABL500
n	62	29
Sxx	0.69	0.74
Syy	1.24	0.53
Slope	1.003	1.016
Int't	-0.8	1.1
Sy.x	1.65	0.32
Xmin	30.4	28
Xmax	99.0	91
r	0.989	0.999

Factors Affecting Results*

Exposing the sample to air allows CO₂ to escape which causes **PCO₂** to decrease and pH to increase and HCO₃ and TCO₂ to be under-estimated. The use of partial-draw tubes (evacuated tubes that are adjusted to draw less than the tube volume, e.g., a 5 cc tube with enough vacuum to draw only 3 cc) is not recommended for use with the i-STAT System because of the potential for decreased measured **PCO₂** results and calculated HCO₃ and TCO₂ values. Under-filling blood collection tubes may also cause decreased **PCO₂** results. Care must also be taken to eliminate “bubbling” of the sample with a pipette when filling a cartridge to avoid the loss of CO₂ in the blood.

Allowing blood to stand (without exposure to air) before testing allows **PCO₂** to increase and pH to decrease, which will cause HCO₃ and TCO₂ to be over-estimated, due to metabolic processes.

For patients administered propofol (Diprivan®) or thiopental sodium (syn. thiomebumal sodium, penthiobarbital sodium, thiopentone sodium, thionembutal, Pentothal Sodium®, Nesdonal Sodium®, IntraVal Sodium®, Trapanal®, and Thiothal Sodium⁷), i-STAT recommends the use of G3+, CG4+, CG8+, EG6+ and EG7+ cartridges, which are free from clinically significant interference at all relevant therapeutic doses. i-STAT does not recommend the use of EC8+ cartridges for patients receiving propofol (Diprivan®) or thiopental sodium.

* It is possible that other interfering substances may be encountered. These results are representative and your results may differ somewhat due to test-to-test variation. The degree of interference at concentrations other than those listed might not be predictable.

References

1. CLSI. *Blood Gas and pH Analysis and Related Measurements; Approved Guideline*. CLSI document C46-A [ISBN 1-56238-444-9]. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA 2001.
2. D.S. Young, *Effects of Drugs on Clinical Laboratory Tests*, 3rd ed. (Washington, DC: American Association of Clinical Chemistry, 1990).
3. P.C. Painter, J.Y. Cope, J.L. Smith, "Reference Ranges, Table 41–20" in *Tietz Textbook of Clinical Chemistry—Second Edition*, C.A. Burtis and E.R. Ashwood, eds. (Philadelphia: W.B. Saunders Company, 1994).
4. E.L. Pruden, O. Siggaard-Andersen, and N.W. Tietz, *Blood Gases and pH*, in *Tietz Textbook of Clinical Chemistry, Second Edition*, ed. C.A. Burtis and E.R. Ashwood. (Philadelphia: W.B. Saunders Company, 1994).
5. CLSI. *Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline*. CLSI document EP9-A [ISBN 1-56238-283-7]. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA 1995.
6. P.J. Cornbleet and N. Gochman, "Incorrect Least-Squares Regression Coefficients in Method-Comparison Analysis," *Clinical Chemistry* 25:3, 432 (1979).
7. *The Merck Index, Eleventh Edition*, Merck & Co., Inc., NJ 1989.

i-STAT is a trademark of the Abbott Group of Companies in various jurisdictions. Diprivan is a registered trademark of the AstraZeneca group of companies. Pentothal Sodium is a registered trademark of Abbott Labs., USA. Nesdonal Sodium is a registered trademark of Specia, France. Intraval Sodium is a registered trademark of May and Baker, Ltd., England. Trapanal is a registered trademark of Chemische Fabrik Promonta, Germany. ABL is a registered trademark of Radiometer Medical A/S, Copenhagen Denmark. BGE is a registered trademark of Instrumentation Laboratory, Lexington MA.



Abbott Point of Care Inc.
100 and 200 Abbott Park Road
Abbott Park, IL 60064 • USA



Emergo Europe
Molenstraat 15
2513 BH The Hague
The Netherlands



©2017 Abbott Point of Care Inc. All rights reserved. Printed in USA.